Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05086848
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05082233
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 298
- Registration Number
- NCT05074589
- Locations
- 🇨🇳
Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command, Nanjing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT05074602
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT05054842
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 345
- Registration Number
- NCT05048134
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05049083
- Locations
- 🇨🇳
the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05047341
- Locations
- 🇨🇳
the first affiliated hospital of Soochow University, Suzhou, Jiangsu, China
Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05046808
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05041920
- Locations
- 🇨🇳
Zhongda Hospital, Affiliated to Southest University, Nanjing, Jiangsu, China
© Copyright 2024. All Rights Reserved by MedPath